Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

被引：0

作者：

Bartsch, R. ^{[1
]}

Harbeck, N. ^{[2
,3
]}

Wrobel, D. ^{[4
]}

Zaiss, M. ^{[5
]}

Terhaag, J. ^{[6
]}

Guth, D. ^{[7
]}

Distelrath, A. ^{[8
]}

Wuerstlein, R. ^{[2
,3
]}

Zahn, M. -O. ^{[9
]}

Lueftner, D. ^{[10
,11
]}

Schwitter, M. ^{[12
]}

Balic, M. ^{[13
]}

Jackisch, C. ^{[14
]}

Mueller, V. ^{[15
]}

Rinnerthaler, G. ^{[16
]}

Schmidt, M. ^{[17
]}

Zaman, K. ^{[18
]}

Schinkoethe, T. ^{[19
]}

Gorray, M. ^{[20
]}

Breitenstein, U. ^{[21
]}

机构：

[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria

[2] LMU Univ Hosp, Dept OB GYN, Breast Ctr, Munich, Germany

[3] LMU Univ Hosp, CCC Munich, Munich, Germany

[4] Sozialstiftung Bamberg Klinikum Bruderwald, Bamberg, Germany

[5] Oncol Practice, Freiburg, Germany

[6] Rottal Inn Clin, Eggenfelden, Germany

[7] Gyneco Oncol Practice Dr Guth, Plauen, Germany

[8] Praxisgemeinschaft Onkol & Urol, Wilhelmshaven, Germany

[9] MVZ Onkol Kooperat Harz, Goslar, Germany

[10] Immanuel Hosp Mark Schweiz, Brandenburg, Germany

[11] Med Univ Brandenburg Theodor Fontane, Brandenburg, Germany

[12] Kantonsspital Graubunden, Chur, Switzerland

[13] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria

[14] Sana Klinikum Offenbach, Dept Gynecol & Obstet, Offenbach, Germany

[15] Univ Hosp Hamburg Eppendorf, Dept Gynecol & Obstet, Hamburg, Germany

[16] Paracelsus Med Univ Salzburg, Dept Internal Med 3, Salzburg, Austria

[17] Univ Hosp Mainz, Dept Gynecol, Mainz, Germany

[18] Lausanne Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland

[19] CANKADO Serv GmbH, Kirchheim, Germany

[20] Pierre Fabre Pharma GmbH, Freiburg, Germany

[21] Brust Zentrum Zurich, Div Oncol, Zurich, Switzerland

来源：

BREAST | 2023年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P014

引用

下载

页码：S20 / S21

页数：2

共 42 条

[21] Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US
Brodtkorb, Thor-Henrik
McDade, Cheryl
Lalla, Deepa
Holmes, Frankie Ann
CANCER RESEARCH, 2021, 81 (04)
[22] Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: HTA-driven analyses from the ExteNET study
Luftner, Diana
Tesch, Hans
Schmidt, Marcus
Hartkopf, Andreas
Streicher, Sarah
Resch, Anna
Genovese, Luca
Rose, Christian
Valenti, Roberta
Harbeck, Nadia
CANCER RESEARCH, 2021, 81 (04)
[23] Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice
Luedtke-Heckenkamp, K.
Kuemmel, S.
Ruf-Doerdelmann, A.
Distelrath, A.
Wacker, J.
Schmatloch, S.
Busch-Liles, S.
Schmidt, M.
ANNALS OF ONCOLOGY, 2017, 28
[24] Quality of life (QoL) and toxicity in patients (pts) with hormone receptor-positive, HER2-negative early breast cancer (HR+, HER2-eBC) treated with adjuvant (adj) endocrine therapy (ET) in the CANcer TOxicities (CANTO) study
Bertaut, A.
Crnjevic, T. Badovinac
Martin, A-L.
Gaudin, C.
Chen, L.
ANNALS OF ONCOLOGY, 2023, 34 : S320 - S321
[25] Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
Lueftner, D.
Tesch, H.
Schmidt, M.
Hartkopf, A.
Streicher, S.
Resch, A.
Genovese, L.
Rose, C.
Valenti, R.
Harbeck, N.
BREAST, 2021, 56 : S17 - S17
[26] Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy-5th interim analysis of the national non-interventional study (NIS) ML21589
Hanker, L.
Hitschold, T.
Grafe, A.
Foerster, F.
Schroeder, J.
Janssen, J.
Reichert, D.
Hielscher, C.
Keitel, S.
Hesse, T.
CANCER RESEARCH, 2016, 76
[27] Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy 5th interim analysis of the national non-interventional study (NIS) ML21589
Hanker, L.
Hitschold, T.
Grafe, A.
Foerster, F.
Schroeder, J.
Janssen, J.
Reichert, D.
Hielscher, C.
Keitel, S.
Hesse, T.
CANCER RESEARCH, 2016, 76
[28] Health Care Reality in Germany and Austria - Second Interim Analysis of the non-interventional Study PERFORM for Patients with HR +/HER2-advanced Breast Cancer who are treated in the First Line with endocrine-based Palbociclib Therapy
Singer, C. F.
Radosa, J.
Fietz, T.
Wilke, J.
Frank, M.
Gratzke, K.
Adams, A.
Buder, A.
Seidel, S.
Lux, M. P.
Bartsch, R.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (04) : 9 - 10
[29] Risk score assessment in clinical routine including gene expression testing - interim results of the non-interventional study PERFORM evaluating Palbociclib in Combination with Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
Fietz, T.
Radosa, J.
Wilke, J.
Decker, T.
Petersen, V.
Deryal, M.
Knoblich, J.
Losem, C.
Rhein, U.
Schoettker, B.
Wrobel, D.
Cordova, Cubas M.
Buncke, J.
Frank, M.
Woerner, S. M.
Adams, A.
Lux, M. P.
Bartsch, R.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 172 - 173
[30] Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
Razavi, Pedram
Ahmed, Mehnaj
Roush, Ashley
Parikh, Rohan
Hitchens, Abigail
Shen, Sherry
Safonov, Anton
Jhaveri, Komal L.
Robson, Mark E.
Peacock, Nancy Walker
Ma, Yanjun
Santarsiero, Elizabeth Chertow
Ganapathy, Vaidyanathan
Shah, Rohan M.
Amefule, Adaeze Q.
Lteif, Agnes
Blakely, L. Johnetta
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →